PDS0104 combines the utility of the Versamune® platform with melanoma antigens, including the Tyrosinase-related Protein 2 (TRP2)-antigen.

About 96,480 new melanomas will be diagnosed this year, more than 7,000 of which will prove fatal.  The rates of melanoma have been rising rapidly over the past few decades.

PDS0104 is currently in late-stage pre-clinical development.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up